Quick Answer
Neumora Therapeutics, Inc. reported Operating Income Loss of -$241.16 million for the year ending 2025.
- Neumora Therapeutics, Inc. showed an increase of +8.5% in Operating Income Loss from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: -$30.60 million | Q1 2023: -$39.17 million | Q2 2023: -$42.06 million | Q3 2023: -$56.86 million | Q1 2024: -$60.07 million | Q2 2024: -$63.82 million | Q3 2024: -$76.65 million | Q1 2025: -$70.94 million | Q2 2025: -$54.04 million | Q3 2025: -$57.70 million.
- Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Operating Income Loss has declined by 77.5%.
- Historical annual values: Fiscal year 2025: -$241.16 million | Fiscal year 2024: -$263.46 million | Fiscal year 2023: -$252.10 million | Fiscal year 2022: -$135.87 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: